Migraine: Epidemiology, Burden, and Comorbidity
- PMID: 31563224
- DOI: 10.1016/j.ncl.2019.06.001
Migraine: Epidemiology, Burden, and Comorbidity
Abstract
Migraine affects an estimated 12% of the population. Global estimates are higher. Chronic migraine (CM) affects 1% to 2% of the global population. Approximately 2.5% of persons with episodic migraine progress to CM. Several risk factors are associated with the progression to CM. There is significant short-term variability in migraine frequency independent of treatment. Migraine is associated with cardiovascular disease, psychiatric disease, and sleep disorders. It is the second most disabling condition worldwide. CM is associated with higher headache-related disability/impact, medical and psychiatric comorbidities, health care resource use, direct and indirect costs, lower socioeconomic status, and health-related quality of life.
Keywords: Chronic migraine (CM); Comorbidity; Headache-related disability; Incidence; Migraine; Prevalence; Progression; Risk factors.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.Neurology. 2019 Dec 10;93(24):e2224-e2236. doi: 10.1212/WNL.0000000000008589. Epub 2019 Nov 5. Neurology. 2019. PMID: 31690685 Free PMC article.
-
Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.Headache. 2018 Nov;58(10):1579-1592. doi: 10.1111/head.13421. Epub 2018 Oct 30. Headache. 2018. PMID: 30375650
-
Migraine and its psychiatric comorbidities.J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):741-9. doi: 10.1136/jnnp-2015-312233. Epub 2016 Jan 5. J Neurol Neurosurg Psychiatry. 2016. PMID: 26733600 Review.
-
Chronic migraine: epidemiology and disease burden.Curr Pain Headache Rep. 2011 Feb;15(1):70-8. doi: 10.1007/s11916-010-0157-z. Curr Pain Headache Rep. 2011. PMID: 21063918 Review.
-
Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers.J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):428-32. doi: 10.1136/jnnp.2009.192492. Epub 2010 Feb 17. J Neurol Neurosurg Psychiatry. 2010. PMID: 20164501
Cited by
-
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.Eur J Neurol. 2024 May;31(5):e16215. doi: 10.1111/ene.16215. Epub 2024 Feb 7. Eur J Neurol. 2024. PMID: 38323742 Free PMC article.
-
Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.Neurology. 2023 Feb 21;100(8):e764-e777. doi: 10.1212/WNL.0000000000201568. Epub 2022 Nov 17. Neurology. 2023. PMID: 36396451 Free PMC article. Clinical Trial.
-
Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.Patient Prefer Adherence. 2024 Jan 9;18:69-88. doi: 10.2147/PPA.S437396. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38223442 Free PMC article.
-
Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs).Curr Neuropharmacol. 2022;20(4):693-712. doi: 10.2174/1570159X19666210517150418. Curr Neuropharmacol. 2022. PMID: 33998993 Free PMC article. Review.
-
Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches.Toxins (Basel). 2022 Sep 5;14(9):619. doi: 10.3390/toxins14090619. Toxins (Basel). 2022. PMID: 36136557 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical